Please use this identifier to cite or link to this item:
Full metadata record
|dc.contributor.advisor||蕭斐元(Fei-Yuan Sharon Hsiao)|
|dc.identifier.citation||1. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-505.
2. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245-8.
3. Deitcher SR. Diagnosis, Treatment, and Prevention of Cancer-Related Venous Thrombosis. In: Abeloff M, Armitage J, JNiederhuber J, Kastan M, McKenna W, eds. Abeloff's Clinical Oncology. 4 ed; 2008:693-715.
4. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011;117:1334-49.
5. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-64.
6. Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006;24:1112-8.
7. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70-6.
8. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost 2011;9:85-91.
9. Cohen AT. Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery. Thromb Haemost 2010;104:919-30.
10. Lee CH, Lin LJ, Cheng CL, Kao Yang YH, Chen JY, Tsai LM. Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population. J Thromb Haemost 2010;8:1515-23.
11. Lee C-H, Cheng C-L, Lin L-J, Tsai L-M, Yang Y-HK. Epidemiology and Predictors of Short-Term Mortality in Symptomatic Venous Thromboembolism. Circ J 2011;75:1998-2004.
12. Oh SY, Kim JH, Lee KW, et al. Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. Thromb Res 2008;122:485-90.
13. Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol 2010;89:201-6.
14. Lee KW, Bang SM, Kim S, et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost 2010;8:540-7.
15. Choi S, Lee KW, Bang SM, et al. Different characteristics and prognostic impact of deep-vein thrombosis / pulmonary embolism and intraabdominal venous thrombosis in colorectal cancer patients. Thromb Haemost 2011;106:1084-94.
16. Yokoyama K, Murata M, Ikeda Y, Okamoto S. Incidence and risk factors for developing venous thromboembolism in Japanese with diffuse large b-cell lymphoma. Thromb Res 2011.
17. Kang MJ, Ryoo BY, Ryu MH, et al. Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience. Eur J Cancer 2012;48:492-500.
18. Jeon HK, Kim DU, Baek DH, et al. Venous thromboembolism in patients with cholangiocarcinoma: focus on risk factors and impact on survival. Eur J Gastroenterol Hepatol 2012;24:444-9.
19. Segal JB, Eng J, Jenckes MW, et al. Diagnosis and treatment of deep venous thrombosis and pulmonary embolism. Evid Rep Technol Assess (Summ) 2003:1-6.
20. Fields JM, Goyal M. Venothromboembolism. Emerg Med Clin North Am 2008;26:649-83, viii.
21. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93.
22. White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 2005;93:298-305.
23. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:1169-73.
24. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657-60.
25. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9.
26. White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 2009;123 Suppl 4:S11-7.
27. Stein PD, Kayali F, Olson RE, Milford CE. Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 2004;116:435-42.
28. Cheuk BL, Cheung GC, Cheng SW. Epidemiology of venous thromboembolism in a Chinese population. Br J Surg 2004;91:424-8.
29. Molina JA, Jiang ZG, Heng BH, Ong BK. Venous thromboembolism at the National Healthcare Group, Singapore. Ann Acad Med Singapore 2009;38:470-8.
30. Kobayashi T, Nakamura M, Sakuma M, et al. Incidence of pulmonary thromboembolism (PTE) and new guidelines for PTE prophylaxis in Japan. Clin Hemorheol Microcirc 2006;35:257-9.
31. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 2009;28:401-9.
32. Anderson FA, Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107:I9-16.
33. Anderson FA, Jr., Wheeler HB. Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg 1992;16:707-14.
34. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-15.
35. Goldhaber SZ. Deep Venous Thrombosis and Pulmonary Thromboembolism. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine. 18th ed. New York: McGraw-Hill; 2012.
36. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445-53.
37. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S.
38. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med 2010;38:S495-501.
39. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-8.
40. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006;368:371-8.
41. Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011;342:d813.
42. Witt DM, Nutescu EA, Haines ST. Venous Thromboembolism. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill Medical; 2011.
43. Blann AD, Lip GY. Venous thromboembolism. BMJ 2006;332:215-9.
44. Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol 2009;27:4889-94.
45. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-4.
46. Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. Thromb Haemost 2007;98:656-61.
47. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-91.
48. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-9.
49. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006;119:60-8.
50. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484-90.
51. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339-46.
52. Cronin-Fenton DP, Sondergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010;103:947-53.
53. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-9.
54. Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost 2010;8:1702-9.
55. Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost 2011;9 Suppl 1:316-24.
56. Hammond J, Kozma C, Hart JC, et al. Rates of venous thromboembolism among patients with major surgery for cancer. Ann Surg Oncol 2011;18:3240-7.
57. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:89-95.
58. Falanga A. The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest 2009;27:105-15.
59. Huang H, Korn JR, Mallick R, Friedman M, Nichols C, Menzin J. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study. J Thromb Thrombolysis 2012.
60. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24.
61. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277-85.
62. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008;6:601-8.
63. Mandala M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007;18:1660-5.
64. Sandhu R, Pan CX, Wun T, et al. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer 2010;116:2596-603.
65. Rodriguez AO, Wun T, Chew H, Zhou H, Harvey D, White RH. Venous thromboembolism in ovarian cancer. Gynecol Oncol 2007;105:784-90.
66. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
67. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653-61.
68. Mandala M, Falanga A, Piccioli A, et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006;59:194-204.
69. National Comprehensive Cancer Network Web site. NCCN clinical pratice guidelines in oncology: Venous Thromboembolic Disease v.2.2011. (Accessed March 30, 2012, at www.ncc.org.)
70. Mandala M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22 Suppl 6:vi85-92.
71. Farge D, Bosquet L, Kassab-Chahmi D, et al. 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol 2010;73:31-46.
72. Debourdeau P, Kassab Chahmi D, Le Gal G, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 2009;20:1459-71.
73. Moll S, Mackman N. Venous thromboembolism: a need for more public awareness and research into mechanisms. Arterioscler Thromb Vasc Biol 2008;28:367-9.
74. Weitz JI. Unanswered questions in venous thromboembolism. Thromb Res 2009;123 Suppl 4:S2-S10.
75. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e419S-94S.
76. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-35.
77. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
78. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-72.
79. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389-96.
80. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:I17-21.
81. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997;84:1099-103.
82. Colwell CW, Jr., Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 1994;76:3-14.
83. Horbach T, Wolf H, Michaelis HC, et al. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement. Thromb Haemost 1996;75:246-50.
84. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005;92:1212-20.
85. Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of venous thromboembolism occurrence in medical patients among the insured population. Thromb Haemost 2009;102:951-7.
86. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325-9.
87. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800.
88. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9.
89. Hsiao FY, Yang CL, Huang YT, Huang WF. Using Taiwan national health insurance research databases for pharmacoepidemiology research. J Food Drug Anal 2007;15:99-108.
90. National Health Insurance Research Database, Taiwan. Introduction to the National Health Insurance Research Database (NHIRD), Taiwan. (Accessed February 15, 2012, at http://w3.nhri.org.tw/nhird//date_01.html.)
91. Lin LY, Lee CH, Yu CC, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-- a nation wide database analysis. Atherosclerosis 2011;217:292-5.
92. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011;63:40-6.
93. Chien IC, Lin CH, Chou YJ, Chou P. Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in Taiwan, 1996-2005: a national population-based study. Soc Psychiatry Psychiatr Epidemiol 2012.
94. Bih SH, Chien IC, Chou YJ, Lin CH, Lee CH, Chou P. The treated prevalence and incidence of bipolar disorder among national health insurance enrollees in Taiwan, 1996-2003. Soc Psychiatry Psychiatr Epidemiol 2008;43:860-5.
95. Parikh S, Shah R, Kapoor P. Portal vein thrombosis. Am J Med 2010;123:111-9.
96. Ponziani FR, Zocco MA, Campanale C, et al. Portal vein thrombosis: Insight into physiopathology, diagnosis, and treatment. World J Gastroentero 2010;16:143-55.
97. Cancer Registry Annual Report, 2008, Taiwan. (Accessed 13 June, 2012, at http://www.bhp.doh.gov.tw/BHPnet/Portal/StatisticsShow.aspx?No=200911300001.)
98. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006;4:529-35.
99. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-20.
100. Kroger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006;17:297-303.
101. Yu YB, Gau JP, Liu CY, et al. A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. Thromb Haemost 2012;108.
102. Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011;70:1083-6.
103. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997;277:642-5.
104. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008;117:93-102.
105. Squizzato A, Ageno W. The 8th American College of Chest Physicians Guidelines – A perspective on venous thromboembolism guidelines. Thromb Haemost 2008.
106. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC medicine 2011;9:1.
107. Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009;101:134-8.
108. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer. Arch Intern Med 2008;168:2377-81.
109. Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100:435-9.
110. Akl EA, Labedi N, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane database of systematic reviews (Online) 2011:CD006650.
111. Chang CH, Chen HC, Lin JW, Kuo CW, Shau WY, Lai MS. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:763-71.
112. Chang CH, Lin JW, Chen HC, Kuo CW, Shau WY, Lai MS. Non-steroidal anti-inflammatory drugs and risk of lower gastrointestinal adverse events: a nationwide study in Taiwan. Gut 2011;60:1372-8.
113. Wittkowsky AK, Nutescu EA. Thrombosis. In: Koda-Kimble MA, Young LY, Kradjan WA, et al., eds. Applied therapeutics : the clinical use of drugs. 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009.
114. Palareti G. Bleeding with anticoagulant treatments. Hamostaseologie 2011;31:237-42.
115. Cohen A, Chiu KM, Park K, et al. Managing venous thromboembolism in Asia: Winds of change in the era of new oral anticoagulants. Thromb Res 2012.
116. Cattaruzzi C, Troncon MG, Agostinis L, Garcia Rodriguez LA. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol 1999;52:499-502.
117. Raiford DS, Perez Gutthann S, Garcia Rodriguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology 1996;7:101-4.
118. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf 2012;21:154-62.
119. Deyo RA, Cherkin DC, Ciol MA. Adapting a Clinical Comorbidity Index for Use with Icd-9-Cm Administrative Databases. J Clin Epidemiol 1992;45:613-9.
120. Zhan C, Battles J, Chiang YP, Hunt D. The validity of ICD-9-CM codes in identifying postoperative deep vein thrombosis and pulmonary embolism. Jt Comm J Qual Patient Saf 2007;33:326-31.
研究目的 本群體觀察性研究(population-based observational study)的目的乃為建立臺灣癌症病人發生靜脈血栓栓塞症的流行病學資料，分析發生靜脈血栓栓塞症的危險因子，並探討其臨床特徵和目前國內的治療現況。
研究方法：本研究以臺灣健保資料庫2000年、2005年和2010年三套百萬人承保抽樣歸人檔為資料來源，找出2001年至2008年住院主診斷為癌症的新診斷癌症病人，並以初次住院主診斷為癌症的入院日期為index date。在index date的住院主診斷有兩個(含)以上的癌症的病人，則被排除在研究之外。本研究的研究終點為index date當天或之後因靜脈血栓栓塞症而住院。本研究共有兩個靜脈血栓栓塞症的定義：定義一為住院檔中出現靜脈血栓栓塞症的診斷，定義二則為住院檔中同時有靜脈血栓栓塞症診斷及靜脈血栓栓塞症的治療。本研究針對所有癌症病人和不同癌症部位的靜脈血栓栓塞症的發生率，及針對發生靜脈血栓栓塞症和沒有發生靜脈血栓栓塞症的病人在年齡、性別、共病症和可能危險因子，連續變項使用t-test，類別分項使用Chi-square或Fisher’s exact test進行分析。針對以定義二而住院的病人，則使用邏輯迴歸模型(logistic regression model)進行分析，找出發生靜脈血栓栓塞症的危險因子，並探討靜脈血栓栓塞症長期治療的狀況、復發率與發生出血性副作用的機率。
研究結果：在43,855名新診斷癌症病人中，1388名(3.2%) (定義一)和473名(1.1%) (定義二)病人在index date當天或之後因靜脈血栓栓塞症而入院。靜脈血栓栓塞症的發生率分別為9.9每1,000人年(1.0 – 68.2每1,000人年) (定義一)和3.4每1,000人年(0.0 – 16.1每1,000人年) (定義二)。靜脈血栓栓塞症發生率較高的癌症包括：肝臟、胰臟、肺臟、多發性骨髓瘤(multiple myeloma)、肉瘤(sarcoma)和非何杰金氏淋巴瘤(non-Hodgkin’s lymphoma)。靜脈血栓栓塞症(定義一)在index date 30天、90天、180天和365天內的累積發生率(cumulative occurrence)分別為42.9%、53.5%、61.7%和70.8%。靜脈血栓栓塞症(定義二)在index date 30天、90天、180天和365天內的累積發生率分別為25.2%、39.8%、47.8%和59.4%。靜脈血栓栓塞症的顯著危險因子包括癌症部位、之前有發生靜脈血栓栓塞症的病史、動脈栓塞症(arterial embolism)、肥胖(obesity)、高血壓、風濕性疾病、接受化學治療、合併治療和胸腔、腹部或泌尿生殖道大手術。三個月內的輸血治療與靜脈血栓栓塞症風險的降低有關。在1,388位因靜脈血栓栓塞症(定義一)住院的病人中，只有33.6%的病人(n=467)在當次住院中有接受抗凝血劑的治療或接受栓塞切除術。在473位因靜脈血栓栓塞症(定義二)住院的病人中，1.5%的病人(n=7)接受栓塞切除術，其他病人則接受肝素(heparin)或低分子量肝素(low molecular weight heparin)作為靜脈血栓栓塞症的初期治療。81個病人(19.5%)在第一次靜脈血栓栓塞症後有復發現象。在415個存活病人中，266個病人(64.1%)有接受靜脈血栓栓塞症的長期治療，其中72.2%的病人(n=192)接受warfarin作為長期治療靜脈血栓栓塞症的藥物。長期治療的時間長度中位數為66天，其中大約三分之二(58.7%, n=156)的病人的治療時間長度小於或等於3個月。
|dc.description.abstract||Background:Venous thromboembolism (VTE) is an increasing clinical problem in cancer patients that results in significant mortality and morbidity. Reports indicated that the incidence of VTE varies among different ethnic populations. Although the clinical guidelines for the prevention of VTE have been suggested in Western countries, the understanding of the epidemiology of VTE in Asian countries remains limited.
Objectives: The goal of this population-based observational study is to explore the epidemiology of VTE among cancer patients in Taiwan, analyze the risk factors for VTE and describe the clinical characteristics and treatment pattern of VTE
Methods: Using three sets of longitudinal health insurance database (LHID 2000, LHID 2005 and LHID 2010), we identified newly diagnosed cancer patients who have been hospitalized with a primary diagnosis of malignant disease between 2001 and 2008. The date when the patient was first hospitalized with a primary diagnosis of malignant disease was defined as the index date. Patients had more than one primary diagnosis of malignant diseases at index date were excluded. Primary endpoint of our study was hospital admission for VTE during or after index date. Two definitions of VTE were adopted in our study. VTE definition 1 was based on VTE diagnosis codes in the inpatient medical claims. VTE definition 2 was based on both the VTE diagnosis codes and management of VTE. The incidence rates of VTE for the entire study cohort and subgroups of patients categorized by sites of cancer were estimated. Differences in age, gender, comorbidities, and potential risk factors for VTE between patients with and without VTE events were analyzed. We use t-test for continuous variables and Chi-square analysis or Fisher’s exact test for discrete variables. Only patients who hospitalized with VTE (definition 2) were included in the logistic regression model to identify the risk factors for VTE. We also describe the long-term treatment pattern of VTE and incidence rates of recurrent VTE and bleeding complications.
Results: Among 43,855 newly diagnosed cancer patients, 1388 (3.2%) (definition 1) and 473 (1.1%) (definition 2) patients were hospitalized for VTE during or after index date. The incidence rates of VTE (definition 1 and definition 2) were 9.9 per 1,000 person-years (1.0-68.2 per 1,000 person-years) and 3.4 per 1,000 person-years (0.0-16.1 per 1,000 person-years), respectively. The incidence rates were higher in certain cancers, particularly cancer of liver, pancreas, lung, multiple myeloma, sarcoma, and non-Hodgkin’s lymphoma. The cumulative occurrence of VTE (definition 1) within 30, 90, 180, and 365 days after index date were 42.9%, 53.5%, 61.7%, and 70.8%, respectively. Cumulative occurrence of VTE (definition 2) within 30, 90, 180, and 365 days after index date were 25.2%, 39.8%, 47.8% and 59.4%, respectively. Significant risk factors for VTE were site of cancer, prior history of VTE, arterial embolism, obesity, hypertension, rheumatologic diseases, chemotherapy, combination therapy and major thoracic, abdominal or urogenital surgery. In contrast, blood transfusion within 3 months was significant associated with reduced risk of VTE. Among 1388 patients who hospitalized with VTE (definition 1), only 33.6% of patients (n=467) received anticoagulant therapy or thromboectomy during the hospitalization. Among 473 patients who hospitalized with VTE (definition 2), 1.5% of patients received thromboectomy, other patients received heparin or low molecular weight heparin for initial treatment of VTE. Eighty-one patients (19.5%) had recurrent VTE after the first VTE event. Of 415 survived patients, long-term anticoagulant therapy was initiated in 266 patients (64.1%), 72.2% of them (n=192) received warfarin alone. The median duration was 66 days. Approximately two-thirds of patients (58.7%, n=156) received ≤ 3 months of long-term anticoagulant therapy.
Conclusions: Although the incidence of cancer-related VTE among Taiwanese is lower than Caucasians populations, it is much higher than Asian general populations, particularly in patients with certain cancers such as multiple myeloma, pancreas, liver, and lung cancer. Most VTE occurred within 1 year after cancer diagnosis. Adherence to treatment guidelines was poor in Taiwan. Treatment and prophylaxis of VTE should be optimized, especially in patients with higher-risk of VTE.
|dc.description.provenance||Made available in DSpace on 2021-05-17T09:16:01Z (GMT). No. of bitstreams: 1|
ntu-101-R99451011-1.pdf: 1627441 bytes, checksum: 1a58c7457580777bd7030c8c1583427b (MD5)
Previous issue date: 2012
List of Figures x
List of Tables xi
Chapter 1 Introduction 1
Chapter 2 Literature Review 3
2.1 Venous Thromboembolism 3
2.1.1 Overview of Venous Thromboembolism 3
2.1.2 Epidemiology of Venous Thromboembolism 3
2.1.3 Risk Factors for Venous Thromboembolism 5
2.1.4 Complications of Venous Thromboembolism 7
2.1.5 Clinical Presentations of Venous Thromboembolism 8
2.1.6 Diagnosis of Venous Thromboembolism 8
2.2 Venous Thromboembolism in Patients with Cancer 10
2.2.1 Overview 10
2.2.2 Epidemiology of Cancer-related VTE 10
2.2.3 The Pathogenesis of VTE in Cancer 11
2.2.4 Risk Factors for Cancer-related VTE 14
2.2.5 Consequences of Cancer-related VTE 17
2.2.6 Treatment of Venous Thromboembolism in Cancer Patients 18
2.2.7 Prevention of Venous Thromboembolism in Cancer Patients 25
2.2.8 Venous Thromboembolism in Asian Patients with Cancer 29
Chapter 3 Study Objective 32
Chapter 4 Materials and Methods 33
4.1 Data Source 33
4.2 Study Population and Study Outcomes 34
4.2.1 Study Cohort 34
4.2.2 Primary Endpoint – Hospital Admission for VTE 36
4.2.3 Baseline Characteristics and Comorbid Diseases 39
4.2.4 Potential Risk Factors for VTE 39
4.2.5 Treatment Pattern of VTE 41
4.2.6 Recurrence of VTE and Bleeding Complications 43
4.3 Statistical Analysis 44
4.3.1 Incidence Rate of VTE 44
4.3.2 Descriptive Analysis 44
4.3.3 Logistic Regression Analysis 45
4.3.4 Statistical Software 45
Chapter 5 Results 47
5.1 Study Cohort 47
5.2 Patient Characteristics of Study Cohort 49
5.3 Incidence Rate and Clinical Characteristics of VTE 50
5.3.1 Incidence Rate of VTE 50
5.3.2 Clinical Characteristics of VTE Events 54
5.4 Risk Factors for VTE 57
5.4.1 Baseline Characteristics, Comorbid Diseases and Potential Risk Factors 57
5.4.2 Multivariate Logistic Regression – Risk Factors for VTE 65
5.5 Treatment Pattern of VTE 67
5.5.1 Initial Treatment of VTE 67
5.5.2 Long-term Treatment of VTE 69
5.6 Recurrence of VTE and Bleeding Complications 71
5.6.1 Recurrence of VTE 71
5.6.2 Bleeding Complications 72
Chapter 6 Discussion 73
6.1 Baseline Characteristics of Study Cohort 73
6.2 Incidence Rate of VTE among Cancer Patients 74
6.3 Clinical Characteristic of VTE 79
6.4 Risk Factors for VTE 80
6.5 Initial Treatment Pattern of VTE 84
6.6 Long-term Treatment of VTE 86
6.7 Recurrence of VTE and Bleeding Complications 88
6.8 Strengths of Our Study 91
6.9 Limitations 91
Chapter 7 Conclusions and Suggestions 93
|dc.title||Epidemiology and Clinical Profile of Venous Thromboembolism in Cancer Patients||en|
|dc.subject.keyword||Venous thromboembolism,cancer,epidemiology,clinical profile,risk factors,National Health Insurance Research Database,||en|
|Appears in Collections:||臨床藥學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.